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Introduction
In recent years there has been increasing interest in
proteinase-activated receptor-2 (PAR-2) as a mediator
of neurogenic inflammation (1) and nociception (2).
The rapid induction of PAR-2 in blood vessels follow-
ing injury (3) points to a potential role in mediating
non-neurogenic inflammatory responses. As a G pro-
tein–coupled receptor that is rapidly desensitized fol-
lowing activation, PAR-2 is generally considered to
mediate only acute inflammatory responses, and
studies performed to date have examined only the
effect of administration of PAR-2 agonists over a
short time (up to 6 hours). Although important in
injury responses, acute inflammation is relatively
short-lived and seldom requires medical intervention.
By contrast, chronic inflammatory responses, typified
by debilitating conditions such as rheumatoid arthri-
tis, are rarely self-limiting and present a greater med-
ical challenge. An important question we wished to
address is whether PAR-2 mediates chronic inflam-
matory processes. We tested this hypothesis by induc-
ing a chronic model of arthritis (a classic example of
chronic inflammatory disease) in PAR-2–deficient
mice. Our results demonstrate that disruption of the
PAR-2 gene results in ablation of chronic arthritis and
that PAR-2 is greatly upregulated in inflamed tissues,
providing strong evidence for a key role of PAR-2 in
mediating chronic inflammation.
Methods
Generation of PAR-2–deficient mice. Homologous recom-
bination in ES cells was used to create a null allele of
the PAR-2 gene, which also incorporated a β-galac-
tosidase reporter gene. A 129/Ola mouse genomic λ
2001 library was screened with a PAR-2 cDNA probe
to isolate cloned DNA for the targeting vector con-
struction. The targeting vector consisted of a total of
approximately 9 kb of cloned genomic DNA se-
quence, which flanked both sides of exon 2 (Figure
1a). An 813-nucleotide internal region of exon 2 con-
tained as a ClaI-SalI restriction fragment was removed
and replaced with the reporter/selection cassette
TAG3/IRES/lacZpA/MC1neopA (4). E14Tg2a ES cells 
cultured according to standard protocol (5) were 
electroporated with NotI-linearized targeting vector
and selected in G418. G418-resistant ES cell clones
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were screened by Southern blot analysis of KpnI-
digested ES cell clone DNAs using hybridization
probes flanking and external to the vector homology
arm sequences (Figure 1a) and targeted clones were
detected at a frequency of approximately 9%. Targeted
ES cells were injected into C57BL/6 blastocysts to gen-
erate chimeras according to standard protocol (6). The
resulting male chimeras were subsequently test
crossed with C57BL/6 females, and germline trans-
mission was confirmed in agouti coat colored test-
cross offspring by Southern blot analysis of KpnI-
digested DNA obtained from tail biopsy (Figure 1b).
Male and female test-cross offspring heterozygous for
the null allele (PAR-2+/–) were intercrossed to generate
homozygous (PAR-2–/–) mice. PAR-2–/– mice were
obtained at a normal mendelian ratio and were phe-
notypically similar to PAR-2+/+ and PAR-2+/– littermates,
exhibiting no macroscopic evidence of any abnormal-
ities. The PAR-2–deficient strain was maintained by
backcrossing heterozygous males with C57BL/6
females (Harland UK Ltd., Loughborough, United
Kingdom) at each generation. Heterozygous mice at
backcross generations three and four were used to set
up intercrosses to generate the homozygous, het-
erozygous, and wild-type littermates used in the exper-
imental analyses described herein. All experimentation
was in accordance with the Animals (Scientific Proce-
dures) Act 1986 of the United Kingdom.
Analysis of PAR-2 expression. Direct evidence for PAR-2
expression in the mouse knee was obtained by RT-PCR
performed on synovial tissue harvested from PAR-2+/+
mice and compared with intestine, which was used as a
positive control (Figure 1c). Total cellular RNA was
extracted from tissue using TRIzol reagent (Invitrogen
Ltd., Paisley, United Kingdom). RT-PCR was performed
using the Reverse Transcription System from Promega
UK (Southhampton, United Kingdom). Aliquots (2 µl)
of cDNA were used as templates for amplification by
PCR using ReddyMix (Abgene, Ashford, United King-
dom) and the following intron spanning PAR-2 primers
5′-ATGCGAAGTCTCAGCCTGGCG-3′ and 5′-GAGAGGAG-
GTCGGCCAAGGCC-3′ to yield a 380-bp PCR product.
The signal yielded by the PAR-2 primer pair was nor-
malized to the PCR product generated by an intron
spanning actin primer pair 5′-GTGGGGCGCCCCAG-
GCACCA-3′ and 5′-CTCCTTAATGTCACGCACGATTTC-3′
(548 bp). Thermal cycling was performed under the 
correct conditions for PCR detection of PAR-2 (7). 
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Figure1 
Generation of PAR-2–deficient mice. (a) Structure of the PAR-2 targeting vector (top), the wild-type PAR-2 allele (middle), and targeted allele
(bottom) resulting from replacement recombination at the dashed crosses. The null allele was created by substitution of a reporter/selection
cassette (dark and light blue boxes) for most of the exon 2 sequence (filled gray box). Non-exon–containing chromosomal and cloned genom-
ic DNA sequence is shown by a thick black line and pBluescript plasmid sequence by a thin black line. Restriction enzyme sites ClaI (C), HindIII
(H), KpnI (K), NotI (N), and SalI (S) are indicated by small arrows, and the sizes of relevant restriction fragments are shown by dotted lines. The
targeted allele was identified by KpnI digestion and hybridization with the 5′ and 3′ flanking probe fragments (gray rectangles). (b) Southern
blot analysis of KpnI-digested genomic DNA prepared from pups from an intercross mating of PAR-2 mice heterozygous (+/–) for the null allele,
demonstrating the presence of viable mice homozygous for the null allele (–/–). (c) RT-PCR for β-actin (548 bp) and PAR-2 (380 bp) mRNA
expression in articular (lane 1 and lane 3, respectively) and intestinal (positive control; lane 2 and lane 4, respectively) tissue from PAR-2+/+
mice. (d) High-power view (oil immersion, differential interference contrast) of a synovial arteriole from a PAR-2–/– mouse. (e) Synovial tissue
from a PAR-2+/+ mouse. β-galactosidase activity absent in endothelial cells (arrow 1) from PAR-2+/+ mice compared with PAR-2–/– tissue. Ery-
throcytes (arrowheads) are clearly visible in the lumen as are surrounding smooth muscle cells (arrow 2). Scale bar: 10 µm.
PCR products were separated on a 1.5% agarose gel and
visualized by ethidium bromide staining. The PAR-2
PCR product was excised from the gel and purified using
the Concert Gel Extraction System (Invitrogen Ltd.), and
its identity was confirmed by sequencing with the
BigDye Terminator method using an ABI 3100 auto-
mated sequencer (Applied Biosystems, Warrington,
United Kingdom) and compared with published data. In
addition, in the targeting vector designed for disruption
of the PAR-2 gene, the sequence of the β-galactosidase
gene is preceded by an internal ribosome entry site
sequence (8) embedded in the exon sequence. Conse-
quently, a bicistronic transcription unit is generated in
which expression of β-galactosidase is brought under
control of PAR-2 transcriptional regulatory elements.
Thus staining for β-galactosidase activity can be used to
monitor expression of the targeted PAR-2 allele. This was
achieved by incubating synovial tissues for 24 hours with
X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyrano-
side; Sigma-Aldrich, Poole, United Kingdom), a sub-
strate of β-galactosidase that yields a blue chromophore
when cleaved by the enzyme. The tissues were then exam-
ined for staining by light microscopy, which revealed
reaction product in the endothelium of synovial blood
vessels from PAR-2–/– mice but a complete absence of
staining in PAR-2+/+ mice (Figure 1, d and e). Images are
contrast-enhanced and color balance optimized.
PAR-2 agonists. PAR-2 agonists used were SLIGRL-
NH2 (Tocris Cookson Ltd., Avonmouth, United King-
dom) and ASKH95 (2-furoyl-LIGKV-OH; Figure 2).
Due to the technical difficulty in synthesizing the
reverse sequence peptide to ASKH95, a structurally
similar peptide, ASKH115 (phenylacetyl-LIGKV-OH;
Figure 2), was used as the control peptide. Acetylation
of the amino terminus of PAR-2 agonists has previ-
ously been shown to eliminate their ability to activate
PAR-2 (9, 10). Furthermore, our own data in
NCTC2544 cells, which stably express human PAR-2
(11), indicate that ASKH95 has an effective concen-
tration for a 50% response (EC50) of 8.3 µM in an inos-
itol turnover assay (12), whereas ASKH115 shows no
PAR-2 activity up to 1 mM. Activation of PAR-2 by the
agonists SLIGRL and SLIGKV is evidenced by their
mobilization of intracellular Ca2+ (10). We find that
ASKH95 induces Ca2+ signaling in NCTC2544 cells
stably expressing human PAR-2 but not in control
cells (data not shown). ASKH95 and ASKH115 were
synthesized on an ABI 430 peptide synthesizer
(Applied Biosystems) using Fmoc chemistry (13). The
side-chain protection groups were Ser(tBu) and
Lys(Boc). HOCt/DIC were used as coupling reagents.
All non-amino acids were coupled through their acid
chloride. The crude peptide was cleaved from the resin
and purified by HPLC (Gilson International France
SAS, Villiers-le-Bel, France). The vehicle for the pep-
tides was 0.9% NaCl.
Induction of inflammation. Chronic arthritis was
induced by injection of Freund’s complete adjuvant (10
mg/ml heat-killed Mycobacterium tuberculosis): 20 µl into
the joint space and periarticular injection of 80 µl,
equally divided among four sites, under general anes-
thesia (O2/N2O/2% halothane) after prior measurement
of knee joint diameter. Joint swelling was assessed by
measuring knee joint diameter using spring-loaded
calipers (Kroeplin GmbH, Schluechtern, Germany).
Acute joint inflammation was induced by intra-artic-
ular injection of 20 µl 2% λ carrageenan and 1% kaolin
(Sigma-Aldrich) in sterile 0.9% saline under general
anesthesia, which was then discontinued. Measure-
ments of knee joint diameter were taken 24 hours later.
The untreated contralateral knee was also measured at
the same timepoint. In four animals, one knee was
injected with sterile vehicle as a control. Repeated
measurements of normal knees on five successive days
were reproducible (coefficient of variation, 2%).
Blood flow measurements. Synovial perfusion was assessed
by laser Doppler imaging (Perimed AB, Stockholm, Swe-
den) of the exposed medial aspect of the mouse knee joint
capsule, a method we have previously validated and used
extensively (14). This involved scanning a low-power (1
mW) laser (635 nm) across the exposed external surface
of the medial aspect of the knee joint. Drugs (100 µl) were
applied topically to the capsule. Blood pressure was mon-
itored by cannulation of the carotid artery.
Histological assessment of arthritis. Knee joints were fixed
in 10% neutral formal saline and then decalcified in 5%
nitric acid for 72 hours, and 6-µm paraffin sections
were prepared. These were stained with hematoxylin,
safranin O, and fast green and evaluated by two
observers blinded to animal genotype and treatment.
The severity of arthritic changes, in terms of cellular
infiltrate, synovial hyperplasia, and cartilage damage,
was scored on a 0–3 scale for each and a total score was
calculated. Maximum possible score per animal was 9.
The scores from the two observers were in close agree-
ment and were therefore averaged.
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Figure 2
Structure of the synthetic peptides ASKH95 (PAR-2 agonist) and
ASKH115 (PAR-2 inactive).
Statistical analysis. Data are expressed as mean ± SEM
and comparisons were performed using the two-tailed
Student t test or one- or two-way ANOVA as appropriate.
Results
Activation of PAR-2 in the knee joint using the native
peptide SLIGRL-NH2 or ASKH95, a synthetic PAR-2
agonist, resulted in joint swelling and hyperemia, well-
recognized indices of inflammation. Topical adminis-
tration of SLIGRL-NH2 (1 µg) to the exposed joint cap-
sule in PAR-2+/+ mice elicited vasodilatation at the
1-minute timepoint (Figure 3a). The same dose of
ASKH95 given to PAR-2+/+ mice produced vasodilata-
tion that was sustained for more than 5 minutes (Fig-
ure 3b), but negligible change in PAR-2–/– mice (Figure
3c), confirming the specificity of this novel agonist for
PAR-2. This is supported by the lack of effect of
ASKH115, the control peptide for ASKH95, in PAR-2+/+
mice (Figure 3, d and e). Furthermore, synovial vasodi-
latation in response to ASKH95 (1 µg) was unaffected
by coadministration of ASKH115 (5 µg), demonstrat-
ing no antagonistic activity of the latter (data not
shown). Consistent with the work of Damiano and col-
leagues (15), higher doses of the PAR-2 agonists elicit-
ed depressor responses in PAR-2+/+ mice, thus compli-
cating measurement of joint perfusion. In contrast,
administration of ASKH95 had no effect on blood
pressure in PAR-2–/– mice, even at a dose of 100 µg, fur-
ther confirming that the effects of this agonist are
mediated through PAR-2.
Following a single intra-articular injection of ASKH95,
joint diameter increased substantially in wild-type mice,
reaching maximum by 24 hours. Unexpectedly, this
increase was sustained for up to 72 hours (Figure 3f).
SLIGRL-NH2 also produced joint swelling, although
with a more rapid onset and shorter duration. ASKH115
failed to elicit significant joint swelling. Injection of
ASKH95 into the knee joint of PAR-2–/– mice resulted in
a response that was significantly lower than that seen in
wild-type mice (P < 0.0001, two-way ANOVA), but was
not significantly different from that following intra-
articular injection of ASKH115 (Figure 3f), pharmaco-
logically confirming the absence of PAR-2. The pro-
longed time course over which ASKH95 mediates
swelling is substantially longer than that observed in pre-
vious studies where maximum paw swelling was reached
within 1–2 hours, but had declined by 6 hours (1, 2). This
may be related to differences in the compounds used,
but differences could also have arisen from the site of
injection (knee joint versus paw) or been due to the
species (mouse versus rat).
The observation that a single dose of ASKH95 leads
to prolonged joint swelling suggests that persistent
endogenous activation of PAR-2 could play a pivotal
role in chronic joint inflammation. This was further
investigated in a murine model of chronic arthritis.
Combined intra- and periarticular administration of
Freund’s complete adjuvant produced a substantial
increase in knee joint diameter, characterized by a rapid
initial increase within 24 hours followed by a more pro-
gressive rise, reaching a plateau by 2–3 weeks after
induction (Figure 4a). The extent of inflammation was
strikingly ablated in PAR-2–/– mice, the magnitude being
fourfold less than in the wild-type (P < 0.0001, two-way
ANOVA), demonstrating the crucial role for this recep-
tor in arthritis. PAR-2+/– mice showed an intermediate
phenotype, the inflammatory response being signifi-
cantly greater than that of PAR-2–/– mice (P < 0.0001,
two-way ANOVA). Completely untreated wild-type ani-
mals had a 10.2% ± 2.4% (n = 7) increase in joint diame-
ter by 28 days, which may explain the absence of reduc-
tion in joint diameter following the acute phase of
inflammation in the PAR-2–/– group.
PAR-2 expression, as demonstrated by β-galactosidase
activity in PAR-2–/– mice, is normally limited to small
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Figure 3
Effects of PAR-2 agonists on synovial perfusion and joint swelling. (a)
Laser Doppler image showing vasodilatation 1 minute after topical
administration of 1 µg of the PAR-2 agonist SLIGRL-NH2 (SLIG) to
PAR-2+/+ mice. (b) ASKH95 (1 µg) administered to PAR-2+/+ mice also
elicits vasodilatation. (c) ASKH95 (1 µg) administered to PAR-2–/–
mice is without effect. (d) The control peptide ASKH115 (1 µg)
administered to PAR-2+/+ mice is without effect. (e) Histogram show-
ing quantitative data for the vasodilator effect of SLIG in PAR-2+/+
mice (+/+ SLIG), ASKH95 in both PAR-2–/– mice (–/– 95) and wild-
type mice (+/+ 95), and ASKH115 in wild-type mice (+/+ 115). Per-
fusion is measured in arbitrary “flux units” and color coded in the
images, with dark blue being the lowest and dark red the highest.
Data are presented as mean ± SEM. n = 5–7. *P < 0.01 compared with
+/+ 95. (f) Intra-articular injection of 100 µg of SLIG in PAR-2+/+ mice
(filled squares) elicits an increase in joint diameter that reaches a max-
imum within 4 hours but declines thereafter. The synthetic PAR-2 ago-
nist ASKH95 (100 µg) produces joint swelling that reaches maximum
by 24 hours and is sustained thereafter in PAR-2+/+ mice (filled circles),
a response that differs significantly compared with the same dose of
this peptide in PAR-2–/– mice (open circles) and control peptide
ASKH115 in wild-type mice (filled triangles). Data are presented as
mean ± SEM; n = 4–10.
arterioles (Figure 4b and Figure 1d), but synovial sam-
ples taken 2–3 weeks after induction of inflammation
showed staining of extravascular cells (Figure 4c); the
density of staining was obvious even to the naked eye
(Figure 4d). PAR-2 upregulation was also observed in
surrounding muscle and skin, presumably from leakage
of adjuvant to these tissues during induction, indicat-
ing that enhanced PAR-2 expression is associated with
chronic inflammatory responses in many tissue types. 
Histological examination of the knee joint at the con-
clusion of the experiment revealed severe arthritic
changes in PAR-2+/+ mice, characterized by cellular infil-
tration, synovial hyperplasia, and damage to articular
cartilage (Figure 5a), with many mice scoring 9/9 (Table
1). In contrast, scores were substantially lower in PAR-2–/–
mice (Figure 5b and Table 1), whose joints displayed sim-
ilar histology to that of untreated animals (Figure 5c).
Heterozygotes showed an intermediate degree of joint
damage (Table 1); the difference between groups was sig-
nificant (P < 0.0001, one-way ANOVA). In additional
experiments, we confirmed that the 129/Ola strain, in
whose ES cells the PAR-2 null allele was created, did not
confer resistance to inflammation in the PAR-2–/– mice
as a consequence of a residual 129/Ola genetic back-
ground component still present at the backcross gener-
ation used. Specifically, the development of adjuvant
arthritis in 129/Ola mice did not differ significantly 
(P = 0.4, two-way ANOVA) from that of wild-type
C57BL/6 mice (see Figure 4a), with the 129/Ola strain
showing a 98% increase in knee joint diameter at day 28.
Acute inflammatory responses to car-
rageenan/kaolin showed a significant 
(P = 0.0016, one-way ANOVA, n = 6–8)
reduction in PAR-2–/– mice (18% ± 3.8%
increase in knee joint diameter at 24
hours) compared with heterozygotes
(25.6% ± 4.3% increase) and wild-type mice
(40.4% ± 3.5% increase), but this effect was
much less pronounced than was the abla-
tion of the chronic inflammatory response.
Discussion
We demonstrate here a key role for PAR-2 in
chronic inflammation, and present three
lines of evidence to support our hypothesis.
Chronic arthritis is ablated in PAR-2–defi-
cient mice, identifying the essential role of
this receptor in chronic inflammation. The
second line of evidence is the long-lasting
development of the cardinal signs of
inflammation — joint swelling and vasodi-
latation — following application of PAR-2
agonists. Thirdly, we present evidence for
substantial PAR-2 upregulation in chroni-
cally inflamed tissues.
Using the native peptide SLIGRL-NH2 or
a novel synthetic peptide, ASKH95, we
demonstrate that direct activation of PAR-2
affects synovial vasculature, resulting in
extravasation and inflammatory hyperemia. However,
the nature of these effects differed considerably.
ASKH95 produced a similar magnitude but longer-
lasting vasodilatation than SLIGRL-NH2, and also
elicited greater joint swelling (72 hours vs. 24 hours)
in PAR-2+/+ mice, although the magnitude of the
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Figure 4
Chronic joint inflammation is inhibited by PAR-2 gene disruption and PAR-2 is
upregulated in inflamed tissues. (a) Comparison of the response to induction of
adjuvant arthritis in PAR-2+/+ mice (filled triangles), PAR-2–/– mice (open circles),
and heterozygous mice (filled squares). An acute (24-hour) phase is followed by
a progressive increase in joint diameter that reached a plateau by about 14 days
in all but the PAR-2–/– group, which did not develop a chronic response. Data are
presented as mean ± SEM; n = 6–8. (b) X-gal staining of normal synovial tissue in
a PAR-2–/– mouse shows a rich density of staining for β-galactosidase activity lim-
ited to endothelial cells along the length of the arteriole. (c) Two weeks after induc-
tion of adjuvant monoarthritis in the PAR-2–/– mouse there is marked discrete
extravascular cellular staining (scale bar: 50 µm for both b and c). (d) X-gal stain-
ing of inflamed synovial tissue excised from the knee joints of four PAR-2–/– mice
shows very dense staining compared with uninflamed tissues from the contralat-
eral knees (scale bar: 5 mm).
Figure 5
Histological evaluation of femoral cartilage integrity. (a) Thirty
days after induction of adjuvant arthritis in a PAR-2+/+ mouse, car-
tilage is completely replaced by pannus that has eroded cortical
bone (arrow). (b) Thirty days after induction of adjuvant arthritis
in a PAR-2–/– mouse. Note the intact appearance of cartilage, sim-
ilar to that in the normal joint. (c) Normal (untreated) knee joint
in a PAR-2+/+ mouse. Sections stained with hematoxylin, safranin
O, and fast green. Scale bar: 100 µm.
response over the initial 6 hours was not different. The
longer duration of the effect of ASKH95 could be due
either to persistent signaling of PAR-2 by this com-
pound or a slow rate of metabolic degradation. We
suggest the latter, since ASKH95 does not lead to pro-
longed Ca2+ signaling compared with SLIGKV-OH
(our unpublished observations). The prolonged effect
of ASKH95 is also unlikely to be due to differences in
concentration of the agonists locally as they have sim-
ilar molecular weights. However, ASKH95 is approxi-
mately 525 times more lipophilic than SLIGRL-NH2,
based on log P values of 0.56 and –2.14, respectively
(calculated with Tsar software; Accelrys Inc., San
Diego, California, USA), which would improve pene-
tration and thus retention in the adipose-rich tissues
of the synovium. Moreover, the substituted moiety
(furoyl) in ASKH95 may reduce its metabolic degra-
dation. The extended effect of ASKH95 in our experi-
ments parallels the finding of Vergnolle et al. (16), who
observed that trans-cinnamoyl-LIGRLO-NH2 caused
persistent edema and cellular infiltrate in the rat paw.
Although the mechanism underlying the prolonged
effect of ASKH95 remains uncertain, the kinetics of
the responses to PAR-2 peptides is significant because
it suggests that PAR-2 can be continually activated in
vivo, despite evidence to suggest it is internalized rap-
idly when stimulated in vitro. The specificity of
ASKH95 for PAR-2, which is expressed in the joint tis-
sues of PAR-2+/+ mice, was confirmed by its lack of vas-
cular effects in PAR-2–/– mice. Moreover, the control
peptide, ASKH115, had no effect in PAR-2+/+ animals.
Although derived from the human PAR-2 agonist
SLIGKV, ASKH95 activates murine PAR-2. This was
investigated using a secreted placental alkaline phos-
phatase assay (17) performed in NG108-15 cells
expressing murine PAR-2; ASKH95 is fourfold more
effective in these cells than is SLIGRL-NH2. This is not
surprising since human and murine PAR-2 receptors
have been shown to respond comparably when acti-
vated by the human and murine PAR-2 agonist pep-
tides SLIGKV and SLIGRL (9), indicating considerable
interspecies cross-reactivity. Using the inositol
turnover assay in NCTC2544 cells, we find ASKH95 to
be about fivefold more effective than SLIGKV (our
unpublished observation), paralleling the findings
obtained in the murine PAR-2–expressing cells.
The most striking finding arose from the pivotal
experiments in the chronic model of inflammation.
This model is characterized by sustained joint swelling
(Figure 4a), marked pannus formation, and cartilage
erosion (Figure 5a). Although we used an aggressive
model of arthritis causing extensive joint destruction
in wild-type mice, signs of joint damage were virtually
absent in PAR-2–deficient mice, indicating the absence
of a key inflammatory component; this results in a
failure of these animals to mount a chronic inflam-
matory response. Notably, although heterozygotes
show an intermediate phenotype, the presence of even
one PAR-2 allele is sufficient to mount a substantial
inflammatory response (∼70% of wild-type; see Figure
4a). The fact that PAR-2 expression is powerfully
upregulated in inflamed tissues, both articular and
extra-articular, provides further evidence implicating
PAR-2 in chronic inflammation and suggests that it is
likely to play a central role in chronic inflammatory
processes in many different tissues and organs. Indeed,
it may be that PAR-2 is a key player in many chronic
inflammatory processes, making it a very important
target for future anti-inflammatory therapies.
Although we were not able to investigate this directly,
it is unlikely that the expression of β-galactosidase (the
lacZ reporter gene product) could be responsible for
the reduced inflammatory response in PAR-2–/– mice.
There is no reported precedent for such an effect, and
indeed, in a study by Yang et al. (18) in which the
eotaxin gene was disrupted in mice with a lacZ reporter
gene insertion, resulting in cell type–specific β-galac-
tosidase expression, there was no reduced response to
various inflammatory challenges in the lung.
An essential role for PAR-2 in chronic inflammation is
unexpected, as previously PAR-2 had been shown to be
significantly involved only in the mediation of neuro-
genic inflammation (1), which is relatively short-lived.
Furthermore, Lindner and colleagues (19) have reported
that although the inflammatory response to surgical
trauma was delayed in PAR-2–deficient mice, this inhi-
bition was not long-lasting. The substantial inhibition
of adjuvant-induced arthritis we observed in the PAR-2–/–
group, coupled with the failure of NK1 receptor deletion
to inhibit adjuvant arthritis (20), suggests that PAR-2
may mediate chronic joint inflammation by non-neuro-
genic mediators, perhaps via the cytokine cascade.
Cytokines are known to play an important role in the
pathogenesis of chronic inflammatory processes, and
are targeted in current “biologic” therapies for rheuma-
toid arthritis. PAR-2 may be instrumental in cytokine
pathways as its activation induces cytokine release from
endothelial cells (21). Furthermore, PAR-2 is known to
activate NF-κB (21) and stimulate prostanoid pathways
(22), both of which are involved in mediating inflam-
mation. Our findings provide the first evidence for 
PAR-2 orchestrating chronic inflammatory responses.
However, the mechanisms which mediate this require
further investigation. We have detected PAR-2 expression
in fibroblasts derived from synovium of patients with
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Table 1
Histological scoring of joint damage in mice with adjuvant-induced
arthritis
Cartilage Hyperplasia Infiltration Total score
Untreated 0 0 0 0
PAR-2+/+ 2.8 3 3 8.8A,B
PAR-2+/– 1 2 2.7 5.7A
PAR-2–/– 0 0.2 0.5 0.7C
AP < 0.001 compared with untreated (control) joints (PAR-2–/– mice did not
differ from untreated mice). BP < 0.001 compared with both PAR-2+/+ and
PAR-2+/– mice. CP < 0.01 compared with PAR-2+/– mice. Bonferroni post hoc
testing. n = 3–7.
rheumatoid arthritis (data not shown), suggesting that
PAR-2 could prove an important future therapeutic lead
for this condition. As PAR-2 is widely expressed and
upregulated in many mammalian tissues, it may have a
ubiquitous role in mediating chronic inflammation
throughout the body, suggesting that our work has wide
medical implications. Although PAR-2 antagonists are
not currently available, our findings point toward devel-
opment of such agents as an exciting avenue for future
anti-inflammatory therapy.
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